Abstract
Between 1974 and 1984 69 adults with acute lymphoblastic leukaemia (ALL) were treated with two different protocols. Fifty-four (78%) of the patients entered complete remission (CR); 27 of these then received a consolidation protocol consisting of daunorubicin, cytosine arabinoside and 6-thioguanine, followed by two courses of intravenous methotrexate 500 mg m-2 with folinic acid rescue. All patients received intrathecal methotrexate and cranial irradiation (24 Gy) followed by maintenance therapy with 6-mercaptopurine and methotrexate for at least 2 years. The median survival for all patients was 23 months from the time of presentation with an actuarial 5-year survival of 21%. The actuarial chance of surviving 5 years in CR for patients receiving the consolidation protocol was 38% compared to 19% for patients receiving no consolidation (P = NS). Only patient age and white cell count at presentation were found to influence the chance of achieving CR and the chance of overall survival. The presence or absence of c-ALL antigen did not influence prognosis. Patients younger than 35 years with low white cell counts at presentation (less than 10 X 10(9)1(-1] had a particularly good prognosis but no patient with T-ALL and no patient older than 50 years old at diagnosis survived more than 18 months.
Full text
PDFSelected References
These references are in PubMed. This may not be the complete list of references from this article.
- Aviles A., Sinco A., Rivera R., Ambriz R., Herrera J. G., Pizzuto J. Treatment of adult acute lymphoblastic leukemia with adriamycin, vincristine, and prednisone. Med Pediatr Oncol. 1983;11(2):141–145. doi: 10.1002/mpo.2950110214. [DOI] [PubMed] [Google Scholar]
- Baccarani M., Corbelli G., Amadori S., Drenthe-Schonk A., Willemze R., Meloni G., Cardozo P. L., Haanen C., Mandelli F., Tura S. Adolescent and adult acute lymphoblastic leukemia: prognostic features and outcome of therapy. A study of 293 patients. Blood. 1982 Sep;60(3):677–684. [PubMed] [Google Scholar]
- Barrett A. J., Joshi R., Tew C. How should acute lymphoblastic leukaemia relapsing after bone-marrow transplantation be treated? Lancet. 1985 May 25;1(8439):1188–1191. doi: 10.1016/s0140-6736(85)92865-x. [DOI] [PubMed] [Google Scholar]
- Bennett J. M., Catovsky D., Daniel M. T., Flandrin G., Galton D. A., Gralnick H. R., Sultan C. The morphological classification of acute lymphoblastic leukaemia: concordance among observers and clinical correlations. Br J Haematol. 1981 Apr;47(4):553–561. doi: 10.1111/j.1365-2141.1981.tb02684.x. [DOI] [PubMed] [Google Scholar]
- Bollum F. J. Terminal deoxynucleotidyl transferase as a hematopoietic cell marker. Blood. 1979 Dec;54(6):1203–1215. [PubMed] [Google Scholar]
- Chessells J. M. Acute lymphoblastic leukemia. Semin Hematol. 1982 Jul;19(3):155–171. [PubMed] [Google Scholar]
- Gottlieb A. J., Weinberg V., Ellison R. R., Henderson E. S., Terebelo H., Rafla S., Cuttner J., Silver R. T., Carey R. W., Levy R. N. Efficacy of daunorubicin in the therapy of adult acute lymphocytic leukemia: a prospective randomized trial by cancer and leukemia group B. Blood. 1984 Jul;64(1):267–274. [PubMed] [Google Scholar]
- Greaves M. F., Brown G., Rapson N. T., Lister T. A. Antisera to acute lymphoblastic leukemia cells. Clin Immunol Immunopathol. 1975 May;4(1):67–84. doi: 10.1016/0090-1229(75)90041-0. [DOI] [PubMed] [Google Scholar]
- Greaves M. F., Janossy G., Peto J., Kay H. Immunologically defined subclasses of acute lymphoblastic leukaemia in children: their relationship to presentation features and prognosis. Br J Haematol. 1981 Jun;48(2):179–197. [PubMed] [Google Scholar]
- Haghbin M., Murphy M. L., Tan C. C., Clarkson B. D., Thaler H. T., Passe S., Burchenal J. A long-term clinical follow-up of children with acute lymphoblastic leukemia treated with intensive chemotherapy regimens. Cancer. 1980 Jul 15;46(2):241–252. doi: 10.1002/1097-0142(19800715)46:2<241::aid-cncr2820460203>3.0.co;2-e. [DOI] [PubMed] [Google Scholar]
- Hardisty R. M., Till M. M., Peto J. Acute lymphoblastic leukaemia: four-year survivals old and new. J Clin Pathol. 1981 Mar;34(3):249–253. doi: 10.1136/jcp.34.3.249. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Henderson E. S., Scharlau C., Cooper M. R., Haurani F. I., Silver R. T., Brunner K., Carey R. W., Falkson G., Blom J., Nawabi I. V. Combination chemotherapy and radiotherapy for acute lymphocytic leukemia in adults: results of CALGB protocol 7113. Leuk Res. 1979;3(6):395–407. doi: 10.1016/0145-2126(79)90036-5. [DOI] [PubMed] [Google Scholar]
- Hoelzer D., Thiel E., Löffler H., Bodenstein H., Plaumann L., Büchner T., Urbanitz D., Koch P., Heimpel H., Engelhardt R. Intensified therapy in acute lymphoblastic and acute undifferentiated leukemia in adults. Blood. 1984 Jul;64(1):38–47. [PubMed] [Google Scholar]
- Jacobs A. D., Gale R. P. Recent advances in the biology and treatment of acute lymphoblastic leukemia in adults. N Engl J Med. 1984 Nov 8;311(19):1219–1231. doi: 10.1056/NEJM198411083111905. [DOI] [PubMed] [Google Scholar]
- Lampert F., Henze G., Langermann H. J., Schellong G., Gadner H., Riehm H. J. Acute lymphoblastic leukemia: current status of therapy in children. Recent Results Cancer Res. 1984;93:159–181. doi: 10.1007/978-3-642-82249-0_6. [DOI] [PubMed] [Google Scholar]
- Leimert J. T., Burns C. P., Wiltse C. G., Armitage J. O., Clarke W. R. Prognostic influence of pretreatment characteristics in adult acute lymphoblastic leukemia. Blood. 1980 Sep;56(3):510–515. [PubMed] [Google Scholar]
- Lister T. A., Whitehouse J. M., Beard M. E., Brearley R. L., Wrigley P. F., Oliver R. T., Freeman J. E., Woodruff R. K., Malpas J. S., Paxton A. M. Combination chemotherapy for acute lymphoblastic leukaemia in adults. Br Med J. 1978 Jan 28;1(6107):199–203. doi: 10.1136/bmj.1.6107.199. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Mertelsmann R., Moore M. A., Clarkson B. Leukemia cell phenotype and prognosis: an analysis of 519 adults with acute leukemia. Blood Cells. 1982;8(3):561–583. [PubMed] [Google Scholar]
- Peto R., Pike M. C., Armitage P., Breslow N. E., Cox D. R., Howard S. V., Mantel N., McPherson K., Peto J., Smith P. G. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer. 1977 Jan;35(1):1–39. doi: 10.1038/bjc.1977.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Ritz J., Pesando J. M., Notis-McConarty J., Lazarus H., Schlossman S. F. A monoclonal antibody to human acute lymphoblastic leukaemia antigen. Nature. 1980 Feb 7;283(5747):583–585. doi: 10.1038/283583a0. [DOI] [PubMed] [Google Scholar]
- Sallan S. E., Ritz J., Pesando J., Gelber R., O'Brien C., Hitchcock S., Coral F., Schlossman S. F. Cell surface antigens: prognostic implications in childhood acute lymphoblastic leukemia. Blood. 1980 Mar;55(3):395–402. [PubMed] [Google Scholar]
- Schauer P., Arlin Z. A., Mertelsmann R., Cirrincione C., Friedman A., Gee T. S., Dowling M., Kempin S., Straus D. J., Koziner B. Treatment of acute lymphoblastic leukemia in adults: results of the L-10 and L-10M protocols. J Clin Oncol. 1983 Aug;1(8):462–470. doi: 10.1200/JCO.1983.1.8.462. [DOI] [PubMed] [Google Scholar]
- Simone J. V., Verzosa M. S., Rudy J. A. Initial features and prognosis in 363 children with acute lymphocytic leukemia. Cancer. 1975 Dec;36(6):2099–2108. doi: 10.1002/cncr.2820360926. [DOI] [PubMed] [Google Scholar]